Duke University

Los Alamos National Security, LLC

Beth Israel Deaconess Medical Center, Inc.

The Uab Research Foundation (the University of Alabama at Birmingham)

Triad National Security, LLC

University of California

University of Pennsylvania

Leland Stanford Junior University

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Boston University

Other

Los Alamos Security, LLC

Bette T Korber

Barton F Haynes

Hua-Xin Liao

Beatrice H Hahn

William M Fischer

Norman L Letvin

Dan H Barouch

George M Shaw

Feng Gao

Peter T Hraber

Karina Yusim

James Theiler

Simon J Perkins

Carla L Kuiken

Robert M De Lorimier

Tanmoy Bhattacharya

Peter D Kwong

John R Mascola

Tongqing Zhou

Ying Ying Li

Mattia Bonsignori

Kevin O Saunders

Julie Decker

Thomas B Kepler

Scott D Boyd

Rebecca M Lynch

Denise Kothe

John Mascola

Jerome H Kim

S Munir Alam

Guido Ferrari

Norman Letvin

Christine Bricault

Denise L Monti

Sandrasegaram Gnanakaran

Morgane Rolland

Peter Kwong

Scott Boyd

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelope selections from individual CH505, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Compositions comprising HIV envelopes to induce CH235 lineage antibodies

The invention is directed to mosaic HIV-1 envelopes, and methods of using the same to induce ADCC responses.

Mosaic HIV-1 envelopes to induce ADCC responses

The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.

Antiviral vaccines with improved cellular immunogenicity

In certain aspects the invention provides HIV-1 immunogens, including envelopes (CH0848) and selections there&#x2014;from, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Compositions and methods for inducing HIV-1 antibodies

The invention features immunogenic compositions and vaccines containing an optimized human immunodeficiency virus (HIV) envelope (Env) polypeptide (e.g., a stabilized trimer of optimized HIV Env polypeptides) or a polynucleotide encoding an optimized HIV Env polypeptide and uses thereof. The invention also features methods of treating and/or preventing a HIV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).

Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

Consensus/ancestral immunogens

The present invention relates, in general, to human immunodeficiency virus-1 (HIV-1) particular, to a polyvalent vaccine for HIV-1 and to methods of making and using same.

Methods of inducing an immune response against HIV-1 using recombinant envelopes with improved coverage

The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).

Antibody evolution immunogens

In certain aspects the invention provides immunogenic compositions comprising CH848 HIV-1 envelopes and their use in methods to induce immune responses in subjects, e.g., human subjects.

Compositions comprising CH848 envelopes and uses thereof

In certain aspects the invention provides a selection of HIV-1 envelopes suitable for use as immunogens, and methods of using these immunogens to induce neutralizing antibodies. In certain embodiments, the immunogens are designed to trimerize. In other embodiments, the immunogens comprise an immune modulating component.

Compositions comprising CH505 envelopes, and trimers

In certain aspects the invention provides HIV-1 immunogens, including envelopes (CH505) and selections therefrom, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Swarm immunization with envelopes from CH505

The present invention relates to peptides and compositions suitable for use in inducing anti-HIV-1 antibodies. The compositions comprise HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such compositions.

MPER-liposome conjugates and uses thereof

Growing community of inventors

Los Alamos, NM, United States of America

Bette T Korber